Isofol Medical AB (publ) (ISOFOL.ST)
SEK 1.86
(0.38%)
SEK 1.86
(0.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -37.02 Million SEK | 74.15% |
| 2022 | -159.72 Million SEK | 19.87% |
| 2021 | -198.48 Million SEK | -9.17% |
| 2020 | -187.06 Million SEK | -12.58% |
| 2019 | -163.15 Million SEK | -89.45% |
| 2018 | -89.69 Million SEK | -20.73% |
| 2017 | -71.87 Million SEK | -12.5% |
| 2016 | -64.81 Million SEK | -57.44% |
| 2015 | -40.57 Million SEK | 0.0% |
| 2011 | -10.42 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -12.12 Million SEK | -14.09% |
| 2024 Q1 | -9.67 Million SEK | -9.11% |
| 2023 Q4 | -10.13 Million SEK | -64.83% |
| 2023 FY | - SEK | 74.15% |
| 2023 Q1 | -13.99 Million SEK | 43.82% |
| 2023 Q2 | -7.15 Million SEK | 48.87% |
| 2023 Q3 | -6.15 Million SEK | 14.03% |
| 2022 Q2 | -53.62 Million SEK | -9.11% |
| 2022 FY | - SEK | 19.87% |
| 2022 Q1 | -49.14 Million SEK | 15.38% |
| 2022 Q4 | -24.9 Million SEK | 22.37% |
| 2022 Q3 | -32.08 Million SEK | 40.17% |
| 2021 Q4 | -58.07 Million SEK | -12.11% |
| 2021 FY | - SEK | -9.17% |
| 2021 Q1 | -44.33 Million SEK | 14.13% |
| 2021 Q2 | -44.97 Million SEK | -1.44% |
| 2021 Q3 | -51.8 Million SEK | -15.19% |
| 2020 Q3 | -31.04 Million SEK | 33.64% |
| 2020 Q4 | -51.63 Million SEK | -66.3% |
| 2020 FY | - SEK | -12.58% |
| 2020 Q1 | -57.59 Million SEK | -18.38% |
| 2020 Q2 | -46.79 Million SEK | 18.76% |
| 2019 FY | - SEK | -89.45% |
| 2019 Q4 | -48.65 Million SEK | -7.5% |
| 2019 Q1 | -30 Million SEK | -39.62% |
| 2019 Q3 | -45.25 Million SEK | -31.89% |
| 2019 Q2 | -34.31 Million SEK | -14.36% |
| 2018 Q4 | -21.49 Million SEK | -24.68% |
| 2018 FY | - SEK | -20.73% |
| 2018 Q2 | -16.89 Million SEK | 29.39% |
| 2018 Q1 | -23.92 Million SEK | 6.45% |
| 2018 Q3 | -17.23 Million SEK | -2.04% |
| 2017 Q3 | -19.86 Million SEK | -44.87% |
| 2017 FY | - SEK | -12.5% |
| 2017 Q1 | -13.19 Million SEK | 56.74% |
| 2017 Q2 | -13.71 Million SEK | -3.92% |
| 2017 Q4 | -25.57 Million SEK | -28.75% |
| 2016 Q4 | -30.5 Million SEK | -250.09% |
| 2016 Q1 | -14.7 Million SEK | -41.56% |
| 2016 FY | - SEK | -57.44% |
| 2016 Q2 | -10.68 Million SEK | 27.36% |
| 2016 Q3 | -8.71 Million SEK | 18.44% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | -10.39 Million SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 89.934% |
| Camurus AB (publ) | 562.54 Million SEK | 106.582% |
| Mendus AB (publ) | -97.84 Million SEK | 62.161% |
| Lipum AB (publ) | -37.11 Million SEK | 0.256% |
| NextCell Pharma AB | -40.98 Million SEK | 9.665% |
| Simris Alg AB (publ) | -22.36 Million SEK | -65.559% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -116.711% |
| Active Biotech AB (publ) | -43.88 Million SEK | 15.638% |
| Amniotics AB (publ) | -27.14 Million SEK | -36.403% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -160.421% |
| BioArctic AB (publ) | 275.38 Million SEK | 113.444% |
| Cantargia AB (publ) | -284.31 Million SEK | 86.978% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -89.101% |
| CombiGene AB (publ) | -35.33 Million SEK | -4.777% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 73.714% |
| Genovis AB (publ.) | 64.57 Million SEK | 157.338% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 67.779% |
| Intervacc AB (publ) | -68.98 Million SEK | 46.326% |
| Kancera AB (publ) | -61.88 Million SEK | 40.177% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -38.237% |
| LIDDS AB (publ) | -39.67 Million SEK | 6.67% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -205.882% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 217.896% |
| OncoZenge AB (publ) | 7.26 Million SEK | 609.551% |
| Saniona AB (publ) | -69.69 Million SEK | 46.877% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 88.338% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 86.872% |
| Xintela AB (publ) | -53.47 Million SEK | 30.759% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 78.197% |
| Ziccum AB (publ) | -20.34 Million SEK | -82.008% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1851300.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 84.418% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1680.0% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -175.661% |
| Corline Biomedical AB | -1.69 Million SEK | -2089.474% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 78.639% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 32.445% |
| Aptahem AB (publ) | -10 Million SEK | -269.899% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 420.582% |
| Fluicell AB (publ) | -25.91 Million SEK | -42.873% |
| Biovica International AB (publ) | -119.5 Million SEK | 69.019% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 12.315% |
| AcouSort AB (publ) | -16.7 Million SEK | -121.661% |
| Abliva AB (publ) | -93.6 Million SEK | 60.448% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 88.397% |
| 2cureX AB (publ) | -35.13 Million SEK | -5.373% |
| I-Tech AB | 30.34 Million SEK | 222.01% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 94.819% |
| Cyxone AB (publ) | -20.41 Million SEK | -81.366% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 63.862% |
| Biosergen AB | 228 Thousand SEK | 16338.596% |
| Nanologica AB (publ) | -62.11 Million SEK | 40.398% |
| SynAct Pharma AB | -222.7 Million SEK | 83.375% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 15.588% |
| BioInvent International AB (publ) | -312.7 Million SEK | 88.16% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 12065.884% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 88254.48% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 84.015% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -320.132% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 65.895% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -222.818% |